Spike Pharmaceuticals Enters Infant Drug Market
Release time:
2020-07-31
Jinder Baby Drug Co., Ltd. Established
Jianfeng Pharmaceutical to Enter Infant Drug Market
News Recently, Zhejiang Jinder Baby Drug Co., Ltd., a Sino-German joint venture controlled by Jianfeng Pharmaceutical, completed registration. Jianfeng Pharmaceutical will use this as a basis to introduce German technology and products and develop the infant drug market.
Zhejiang Jinder Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical Co., Ltd., Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 2000 yuan, of which Jianfeng Pharmaceutical Co., Ltd. contributed 1100 yuan in cash, accounting for 55% of the registered capital ; ge Fu Pharmaceutical invested ,500 yuan, accounting for 25% of the registered capital, with two proprietary technologies of "diazepam suppository" and "paracetamol suppository". De Yunjia contributed 400 yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children.
In this cooperation, Gefu Pharmaceuticals has invested in "diazepam suppository" and "acetaminophen suppository" with proprietary technology evaluation. The corresponding products have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension. Acetaminophen is used for fever caused by cold or cold, and is also used to relieve mild to moderate pain. After the establishment of the joint venture company, it will carry out research and development and operation of corresponding products on the basis of these two proprietary technologies.
With the adjustment of my country's population policy and the implementation of the "comprehensive two-child" policy, it is expected that the infant drug market will usher in opportunities for rapid growth. This time, through the establishment of a joint venture company and the introduction of German technology to develop infant drugs, It is an important step taken by Jianfeng Pharmaceutical in response to market demand, and it is also the specific implementation of the company's development strategic plan to expand and strengthen its pharmaceutical business. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page